[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shenyang Sunshine Pharmaceutical Co., LTD.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":426},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,43,68,90,111,131,152,172,192,214,235,254,277,299,320,343,363,384,404],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642580","phase-2-ssgj-705-plus-ssgj-612--chemotherapy-in-advanced-her2-expressing-solid-tumors-100642580",false,"NCT07646626","SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","Inclusion Criteria:\n\n* Males and\u002For females over age 18\n* Histologically and\u002For cytologically documented local advanced or metastatic Colorectal adenocarcinoma (CRC), Urothelial Cancer (UC), Breast Cancer (BC), Biliary Tract Carcinoma(BTC), Gastric\u002FGastroesophageal Junction Cancer （G\u002FGEJC) , etc.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Any remaining adverse events (AEs) \\> grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events（CTCAE） v6. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Inadequate organ or bone marrow function. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.",[27],"Locally Advanced (Unresectable) or Metastatic Solid Tumors",[29],"advanced malignancies","RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-15","ACTUAL",{"date":36,"type":21},"2026-07-31",{"date":38,"type":21},"2028-10-31",{"name":40,"class":41},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100640014","phase-1-a-study-of-sss68-following-a-single-subcutaneous-administration-in-healthy-adult-participants-100640014","NCT07606976","A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamic and Immunogenicity of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants","Inclusion Criteria:\n\n1. Able to understand and comply with protocol requirements, voluntarily participate in the trial and sign a written informed consent form (ICF).\n2. Male or female participants aged 18-45 years (inclusive) when signing the ICF.\n3. Male participants with body weight ≥ 50 kg, and female participants with body weight ≥ 45 kg.\n4. Participants whose vital signs, physical examination results, laboratory test results, 12-lead electrocardiogram (ECG) and other test results are normal, or abnormal without clinical significance as determined by the investigator.\n5. IgG\u002FIgM\u002FIgA \\> upper limit of normal value at the screening Visit.\n6. Female participants with childbearing potential and male participants (and their female partners) must agree to take highly effective contraceptive measures and have no plan of childbearing, sperm donation, or egg donation from screening through at least 6 months after the dose of study drug.\n\nExclusion Criteria:\n\n1. History of severe allergy, or with a history of allergy to the investigational drug, any of its components, or related excipients.\n2. With any clinically significant diseases (including but not limited to gastrointestinal, hepatic, renal, neurological, hematological, endocrine, tumor, pulmonary, immunological, psychiatric, or cardiovascular diseases) prior to the screening visit.\n3. Had any confirmed or suspected immunosuppressive or immune-deficient condition, including but not limited to history of opportunistic infections, asplenia, or primary immunodeficiency.\n4. History of recurrent or chronic infections, or any infection requiring hospitalization or intravenous antiviral\u002Fantibiotic treatment within 6 months before dosing.\n5. Participants with positive test results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus (HIV) antibody.\n6. Participants who have undergone major surgery within 6 months before dosing, or plan to undergo major surgery during the study.\n7. Participants who have received any marketed or investigational biological agent within 5 half-lives or 12 weeks (whichever is longer) before dosing.\n8. Participants who have used any prescription drugs, over-the-counter medications, vitamin supplements, or herbal products within 4 weeks or 5 half-lives (whichever is longer) before dosing.\n9. Participants who smoke more than 5 cigarettes per day within 3 months prior to screening.\n10. History of significant alcohol abuse or regular use of alcohol within 6 months prior to the screening visit.\n11. History of significant drug abuse, or any use of soft drugs within 3 months prior to screening, or any use of hard drugs within 1 year prior to screening, or positive result for urine drug screen test at screening.\n12. Participants who have been vaccinated with live or live-attenuated vaccines within 30 days before dosing, or plan to receive vaccination during the study.\n13. Participation in another interventional clinical trial within 3 months prior to screening.\n14. Participants who have donated blood (≥ 400 mL) or lost a lot of blood (≥ 400 mL) within 3 months before screening.\n15. QTcF ≥450 ms at the screening visit.\n16. Participants who have other factors making participation in this trial inappropriate, as judged by the investigator.",true,"45 Years",{"count":53,"type":21},50,[55],"PHASE1","This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, PD and immunogenicity of SSS68 in healthy adult participants following a single subcutaneous administration.",[58],"Healthy","NOT_YET_RECRUITING","2026-05-19",{"date":62,"type":34},"2026-05-26",{"date":64,"type":21},"2026-06",{"date":66,"type":21},"2026-12",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100630428","phase-1-safety-tolerability-pharmacokinetics-pharmacodynamics-and-immunogenicity-of-sss67-in-healthy-adult-participants-via-single-intravenous-infusion-100630428","NCT07487545","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion","Inclusion Criteria:\n\n* Participants aged 18 to 65 years (inclusive), regardless of gender.\n* Participate in the clinical trial voluntarily and provide informed consent form.\n* At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) must be between 18.5 and 32 kg\u002Fm² (inclusive).\n* At screening, the following must be within normal ranges or assessed by the investigator as abnormal but not clinically significant: Vital signs、Physical examination、12-lead electrocardiogram (ECG)、Chest X-ray (posteroanterior view) or lung computed tomography (CT)、Ultrasound (abdominal, urological, and gynecological \\[for females only\\])、Clinical laboratory tests (including hematology, urinalysis, blood biochemistry, coagulation, serum virolgy and thyroid function).\n* Female participants with childbearing potential and male participants (and their female partners) must agree to take highly effective contraceptive measures and have no plan of childbearing, sperm donation, or egg donation from screening through at least 6 months after the last dose of investigational drug.\n* Able to understand and comply with protocol requirements.\n\nExclusion Criteria:\n\n* History of significant drug or food allergies; or known clinically significant hypersensitivity to the study intervention or related compounds.\n* History of risk factors for torsades de pointes (e.g., heart failure\u002Fcardiomyopathy or family history of long QT syndrome), uncorrected hypokalemia or hypomagnesemia (one retest may be allowed per Investigator's judgment), or QT (QTcF) interval \\>450 ms.\n* Any clinically significant medical condition or illness that could compromise participant safety or interfere with study results.\n* History of any malignancy within the past 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ, or cervical carcinoma in situ th with no evidence of metastatic disease for 3 years.\n* Known concomitant conditions affecting skeletal muscle, or use of any medications or supplements known to influence muscle anabolism\u002Fcatabolism within 3 months prior to screening.\n* History of gastrointestinal surgery resulting in malabsorption, or chronic use of medications that s directly affect gastrointestinal motility. Examples: history of bariatric surgery\u002Fprocedures (e.g., gastric banding), use of medications\u002Fproducts deemed by the investigator to cause weight change and affect weight assessment within 3 months prior to dosing, or intention to use weight-loss drugs during the study.\n* Use of any prescription drugs or over-the-counter medications, herbal medicines, or dietary supplements within 4 weeks prior to screening (participants may be enrolled if the investigator confirms the time interval between last use and the first dose in this trial is \\>5 half-lives of the drug).\n* Use of drugs potentially affecting follicle-stimulating hormone (FSH) levels within 90 days prior to screening, or planned use during the study.\n* Regular weightlifting, bodybuilding, or strength training aimed at increasing muscle mass.","65 Years",{"count":77,"type":21},52,[55],"This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, preliminary PD and immunogenicity of SSS67 in healthy adult participants after single intravenous infusion.\n\nThe primary objective is to assess the safety and tolerability of SSS67 following single ascending doses.\n\nThe secondary objectives are to characterize the PK, PD, and anti-drug antibody (ADA) profiles of SSS67 after single administration.\n\nThe exploratory objective is to evaluate changes in body weight, waist circumference, and other related metabolic parameters following a single dose of SSS67.",[58],"2026-03-17",{"date":83,"type":34},"2026-03-23",{"date":85,"type":21},"2026-03-31",{"date":87,"type":21},"2027-04-02",{"name":40,"class":41},2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100627182","phase-1-the-study-is-to-evaluate-the-safety-and-tolerability-of-spgl008-alone-or-in-combination-with-bcg-in-the-patients-with-nmibc-and-to-determine-the-rp2d-of-spgl008-alone-or-in-combination-with-bcgto-evaluate-the-preliminary-efficacy-of-spgl008-alone-or-in-combination-with-bcg-100627182","NCT07445308","The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.","Phase I\u002FII Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of SPGL008 as Monotherapy or in Combination With BCG in Patients With Non-Muscle-Invasive Bladder Cancer","Inclusion Criteria:\n\n1. Voluntarily participate in this clinical study, understand the research procedures and be able to sign the informed consent in writing;\n2. Age ≥ 18 years old, gender is not limited;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2;\n4. Expected survival time ≥ 2 years;\n5. High-risk NMIBC diagnosed by previous pathological biopsy\n6. ineligible or unwilling to undergo radical cystectomy;\n7. The level of organ function is good.\n\nExclusion Criteria:\n\n1. Currently receiving study treatment in other clinical trials or less than 4 weeks from last participation to the first administration of this study;\n2. Upper urinary tract tumor detected by CTU or MRU during screening period, urethral prostate tumor detected by cystoscopy, or other concomitant malignant tumors within 5 years before the first administration;\n3. Previous medical history or examination suggests active tuberculosis within 1 year prior to the first dose;\n4. Serious infection within 4 weeks before the first administration, or undefined fever\\>38.5 ℃ during screening\u002Fbefore the first administration;\n5. Obvious urinary tract infections and gross hematuria, indicating safety issues assessed by the investigators;\n6. Patients who discontinued treatment due to adverse reactions such as toxemia, systemic infection or urinary incontinence during previous BCG treatment",{"count":98,"type":21},120,[55,24],"The goal of clinical trial is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With on-Muscle-Invasive Bladder Cancer.\n\nThe main questions it aims to answer are:\n\n1. Determine the recommend Phase II dose of SPGL008 Alone or in Combination With BCG.To\n2. Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.",[102],"NMIBC","2026-03-02",{"date":105,"type":34},"2026-03-03",{"date":107,"type":21},"2026-03-12",{"date":109,"type":21},"2029-12-21",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":42},"100597460","phase-1-safety-tolerability-pk-and-pd-of-sss55-in-healthy-subjects-100597460","NCT07058779","Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SSS55 Injection in Healthy Subjects in China","Inclusion Criteria:\n\n1. Healthy subjects aged 18 to 45 years old (including the boundary value), regardless of gender;\n2. The subjects voluntarily participated in the clinical trial and signed the informed consent form;\n3. Men with a weight of ≥50 kg, women with a weight of ≥45 kg, and those with a body mass index (BMI) ranging from 19 to 28 kg\u002Fm2 (including the critical value);\n4. Those who underwent vital sign assessment, physical examination, blood routine, urine routine, blood biochemistry, coagulation function, pregnancy examination (for women of childbearing age), 12-lead ECG, chest X-ray\u002Flung CT during screening, and the results showed no abnormalities or the abnormalities had no clinical significance;\n5. Be willing to receive the MV-ACYW meningococcal vaccine and pneumococcal vaccine 14 days or more before randomization.\n\nExclusion Criteria:\n\n* 1\\) Those with a clear history of drug or food allergies, or a known history of hypersensitivity reactions that are clinically significant to the research intervention measures or related compounds or commonly used antibacterial agents;\n\n  2\\) Those with a history of any serious clinical diseases in the past or present, including but not limited to those in the digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, immune system, neuropsychiatric system, hematological system, etc. (except those deemed eligible for enrollment by the researcher);\n\n  3\\) First-degree relatives with a known history of meningococcal infection or a history of meningococcal infection;\n\n  4\\) Those with contraindications to meningococcal vaccination (with a history of epilepsy or other brain diseases, etc.);\n\n  5\\) There was or suspected active viral, bacterial, fungal or parasitic infection within 14 days prior to screening, including herpes, shingles or cold sores;\n\n  6\\) A history of recurrent infections of unknown cause; Or systemic antibiotics (intravenous antibiotics, oral antibiotics, etc., excluding topical application antibiotics) have been used within 90 days before administration;\n\n  7\\) There is a history of Gilbert syndrome or the researcher assesses that it meets the diagnostic criteria for the disease;\n\n  8\\) Received treatment with blood products within 6 months prior to administration;\n\n  9\\) Those who have undergone major surgical operations within 4 weeks prior to administration or have not fully recovered from any previous invasive procedures;\n\n  10\\) Suffering from syphilis (Treponema pallidum antibody positive) or AIDS (HIV antibody positive), or active hepatitis C (hepatitis C virus antibody positive), or active hepatitis B (hepatitis B surface antigen positive);\n\n  11\\) A history of malignant tumors in the past or present;\n\n  12\\) Any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.) or health supplements have been used within 2 weeks before administration (if determined by the investigator, the time interval from the start of administration of the drug in this trial \\> Five half-lives, and the corresponding subjects can also be enrolled.",{"count":119,"type":21},26,[55],"This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.",[123],"Safety Issues","2026-02-26",{"date":103,"type":34},{"date":127,"type":34},"2025-08-04",{"date":129,"type":21},"2027-12",{"name":40,"class":41},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100595865","phase-1-a-phase-i-study-of-spgl008-in-subjects-with-advanced-malignant-tumors-100595865","NCT07038005","A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SPGL008 Monotherapy for Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n1. Males and\u002For females, 18-75 years old;\n2. Histologically and\u002For cytologically documented advanced or metastatic malignant Tumors;\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n4. Expected survival \\>=3 months;\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease;\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI-CTCAE\\] v.5.0);\n3. Inadequate organ or bone marrow function;\n4. Pregnant or breast-feeding woman;\n5. Known allergies, hypersensitivity, or intolerance to SPGL008.",{"count":139,"type":21},96,[55],"This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.",[143],"Advanced Malignant Tumors","2026-02-05",{"date":146,"type":34},"2026-02-09",{"date":148,"type":34},"2025-07-30",{"date":150,"type":21},"2027-06-08",{"name":40,"class":41},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":42},"100594211","phase-1-a-phase-1-study-of-ssgj-709-in-patients-with-advanced-malignant-tumors-100594211","NCT07016490","A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors","A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SSGJ-709 in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Minimum life expectancy of 3 months;\n* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) score of 0-1;\n* Locally advanced or metastatic malignant tumors confirmed by histopathology or cytology; preferred tumor types for enrollment include head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal squamous cell carcinoma or adenocarcinoma, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, urothelial carcinoma, and clear cell renal cell carcinoma. Subjects with other tumor types may be enrolled after discussion with the sponsor；\n* Subject who have failed, or has been intolerant to standard therapy, or has been considered lack standard of care for a given tumor type, and who is not able to complete surgical resection and receive curative concurrent\u002Fsequential chemoradiotherapy；\n* Having at least one measurable tumor lesion as the target lesion assessed per RECIST v1.1；\n* The subject has adequate hematological and organ functions；\n\nExclusion Criteria:\n\n* Presence of brainstem, meningeal metastases, spinal cord metastases or compression；\n* Presence of active central nervous system (CNS) metastases；\n* Subjects with pleural effusion, pericardial effusion, or ascites that are clinically symptomatic or require repeated drainage；\n* Subjects with other malignant tumors within 3 years prior to screening；\n* Subjects with autoimmune diseases that require systemic treatment within 2 years before screening；\n* Subjects are positive for human immunodeficiency virus (HIV)；\n* Prior or current presence of non-infectious pneumonia\u002Finterstitial lung disease requiring systemic therapy with glucocorticoids；\n* Serious infection within 4 weeks prior to the first dose or the presence of any active infection requiring systemic anti-infective therapy.\n* Having received the following treatments prior to the first dose of study treatment:\n\n  1. Having received anti-tumor therapies such as biological agents, chemotherapy and other investigational drugs not approved for marketing within 3 weeks prior to the first dose of study treatment (Patient may be enrolled if the first dose of study treatment is more than 5 half-lives of the drug from the last anti-tumor therapy);\n  2. Having received small molecule targeted antineoplastic agents (e.g., tyrosine kinase inhibitor), or palliative local therapy for non-target lesions, or non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor) within 2 weeks prior to the first dose;\n  3. Having received herbal medicine with an anti-tumor indication within 1 week prior to the first dose;\n  4. Prior immunotherapy other than anti-PD-(L)1 therapy (Patients with prior immunotherapy against other targets may be enrolled after discussion and agreement with the sponsor).",{"count":160,"type":21},15,[55],"This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.",[143],"2026-01-26",{"date":166,"type":34},"2026-01-28",{"date":168,"type":34},"2025-06-12",{"date":170,"type":21},"2027-12-30",{"name":40,"class":41},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":42},"100606135","phase-2-a-phase-ii-study-of-ssgj-706-monotherapy-and-combination-therapy-in-advanced-non-small-cell-lung-cancernsclc-patients-100606135","NCT07171606","A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","Inclusion Criteria:\n\n1. Males and\u002For females over age 18\n2. Histologically and\u002For cytologically documented local advanced or metastatic NSCLC .\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=3 months.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-706\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":179,"type":21},240,[24],"This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC",[183],"First-line Advanced NSCLC Patients","2025-12-10",{"date":186,"type":34},"2025-12-18",{"date":188,"type":34},"2025-10-24",{"date":190,"type":21},"2027-08-31",{"name":40,"class":41},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":42},"100610920","phase-2-a-phase-ii-clinical-study-evaluating-ssgj-706-in-combination-therapy-for-advanced-gastrointestinal-cancers-100610920","NCT07233850","A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","Inclusion Criteria:\n\n1. Volunteer to participate in this study, willing to follow all trial procedures, and sign the informed consent form (ICF).\n2. Age 18-75 years old, male or female.\n3. Has a life expectancy of at least 3 months\n4. ECOG score of 0-1.\n5. Locally advanced or metastatic tumors of the digestive system that cannot be curatively resected and cannot be treated with radical chemoradiotherapy, including gastric\u002Fgastroesophageal junction adenocarcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and oesophageal cancer.\n6. No prior systemic therapy in the locally advanced unresectable\u002Fmetastatic setting.\n7. Has at least 1 measurable lesion per RECIST version 1.1.\n8. Willing to provide a paraffin-embedded (FFPE) specimen or an unstained histopathological section (preferably a newly obtained tumor tissue sample).\n9. Has bone marrow, kidney, liver, blood and clotting test results required per protocol.\n10. Female subjects of childbearing age had a negative serum pregnancy test within 7 days before the first dose. Male and female subjects of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until at least 120 days after the last use of study drug and for at least 180 days after the last use of chemotherapy drugs or bevacizumab. During this period, women are not lactating, male subjects are not allowed to freeze or donate sperm, and female subjects are not allowed to donate eggs or retrieve eggs for personal use.\n\nExclusion Criteria:\n\n1. For gastric\u002Fgastroesophageal junction adenocarcinoma: HER2-positive (defined as IHC 3+, or IHC 2+ with ISH-positive).\n2. For colorectal cancer: Patients with known MSI-H or dMMR.\n3. Presence of brainstem, meningeal metastases, spinal cord metastases, or compression.\n4. Presence of active central nervous system (CNS) metastases; Subjects with previously treated brain metastases (such as surgery, radiotherapy) are allowed to enroll if they are clinically stable for at least four weeks after treatment (until the first dose of study drug) and corticosteroids are discontinued 3 days before the first dose of study drug; Subjects with untreated, asymptomatic brain metastases can be enrolled.\n5. Previous immunotherapy, including immune checkpoint inhibitors (e.g., PD-l\u002FL1 antibody, anti-CTLA-4 antibody, anti-TIGIT antibody, anti-LAG3 antibody, etc.), immune checkpoint agonists (e.g., ICOS, CD40, CD137, OX40 antibody, etc.), immune cell therapy and any other treatment targeting the mechanism of anti-tumor immune action.\n6. Adverse reactions caused by previous anti-tumor therapy need to be restored to grade ≤1 (as judged by NCI-CTCAE 5.0 criteria), except for alopecia and fatigue.\n7. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n8. Prior or current non-infectious pneumonitis\u002Finterstitial lung disease requiring systemic glucocorticoid therapy.\n9. History of severe bleeding tendency or coagulation dysfunction.\n10. Presence of gastrointestinal perforation and\u002For fistula, intra-abdominal abscess within 6 months before the first dose.\n11. Subjects with known active tuberculosis (TB).\n12. Known history of severe allergy to any component of the trial drug, or history of severe allergic reaction to chimeric or humanized antibodies.\n13. Other conditions that, in the opinion of the investigator, may increase study-related risks or interfere with the interpretation of study results.",{"count":199,"type":21},300,[24],"This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors. Its objective is to assess the safety, tolerability, and antitumor activity of SSGJ-706 in combination with standard treatment.",[203,204,205,206],"Gastric\u002FGastroesophageal Junction Adenocarcinoma","Metastatic Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Oesophageal Cancer","2025-11-14",{"date":209,"type":34},"2025-11-18",{"date":211,"type":21},"2025-11",{"date":129,"type":21},{"name":40,"class":41},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":234,"locationsCount":42},"100594634","phase-2-ssgj-705-monotherapy-and-combination-therapy-in-advanced-her2-expressing-solid-tumors-100594634","NCT07022002","SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors","Inclusion Criteria:\n\n* Males and\u002For females over age 18.\n* Histologically and\u002For cytologically documented local advanced or metastatic non-Small Cell Lung Cancer（NSCLC），Breast Cancer（BC）or Gastric\u002FGastroesophageal Junction Cancer （G\u002FGEJC).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Any remaining adverse events (AEs) \\> grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events（CTCAE） v5. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth.\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Inadequate organ or bone marrow function.",{"count":222,"type":21},340,[24],"This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.",[226],"Locally Advanced, Recurrent or Metastatic Malignancies",[29],"2025-08-01",{"date":230,"type":34},"2025-08-03",{"date":148,"type":34},{"date":233,"type":21},"2027-12-12",{"name":40,"class":41},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":253,"locationsCount":42},"100595426","phase-1-a-phase-i-study-of-ssgj-612-in-patients-with-advanced-solid-tumors-100595426","NCT07032298","A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors","Phase I Clinical Study on the Safety, Pharmacokinetics and Antitumor Activity of SSGJ-612 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Voluntarily participate in this study, be willing to follow and complete all trial procedures, and sign the informed consent form;\n2. Aged ≥18 and ≤75 years old at the time of signing the ICF, regardless of gender;\n3. Expected survival ≥3 months;\n4. Performance status (PS) score of 0-1 according to the Eastern Cooperative Oncology Group (ECOG) scale;\n5. Patients with pathologically or cytologically confirmed locally advanced or metastatic malignant tumors who have failed standard treatment, are intolerant to standard treatment, or have no standard treatment available, and cannot undergo complete surgical resection or receive radical concurrent\u002Fsequential chemoradiotherapy;\n6. Tumor tissue with HER2 expression;\n7. At least one measurable tumor lesion assessed as the target lesion according to RECIST v1.1 criteria, and the lesion is suitable for repeated and accurate measurement.\n\nExclusion Criteria:\n\n1. Presence of brainstem, meninges, or spinal cord metastasis, or spinal cord compression;\n2. Presence of active central nervous system (CNS) metastatic lesions;\n3. Individuals with clinical symptoms or requiring repeated drainage (once a month or more frequently) of pleural effusion, pericardial effusion, or ascites;\n4. Primary or secondary immunodeficiency, including positive human immunodeficiency virus (HIV) test;\n5. Known active tuberculosis; known active syphilis infection;\n6. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n7. Use of any live vaccine or attenuated live vaccine within 4 weeks before the first dose, or plan to receive any live vaccine or attenuated live vaccine during the study;\n8. Known severe allergic history to any component of the investigational drug, or history of severe allergic reaction to antibodies;\n9. Pregnant or lactating women.",{"count":243,"type":21},30,[55],"This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.",[143],"2025-07-22",{"date":249,"type":34},"2025-07-25",{"date":251,"type":34},"2025-07-18",{"date":64,"type":21},{"name":40,"class":41},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":42},"100592472","phase-1-phase-i-study-of-hbt-708-for-patients-with-advanced-solid-tumors-100592472","NCT06993870","Phase I Study of HBT-708 for Patients With Advanced Solid Tumors","A Phase I Study to Evaluate the Safety, Tolerability, and Initial Efficacy of HBT-708 Monotherapy for Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Male or female subjects, age 18 years or older.\n2. Histologically and\u002For cytologically documented advanced or measurable solid tumors.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Life expectancey \\> = 3 months.\n5. Willingness to provide written informed consent for the study.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Subjects must have recovered (≤ Grade 1 or pretherapy baseline) from AEs due to previously administered therapies. (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to HBT-708 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":262,"type":21},60,[55],"The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.",[266],"Advanced Solid Tumors",[268],"solid tumors","2025-07-08",{"date":271,"type":34},"2025-07-11",{"date":273,"type":34},"2025-06-16",{"date":275,"type":21},"2027-06-28",{"name":40,"class":41},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":42},"100591426","phase-3-ssgj-707-in-advanced-non-small-cell-lung-cancer-100591426","NCT06980272","SSGJ-707 in Advanced Non-Small Cell Lung Cancer","A Randomized Controlled, Multi-center Phase III Clinical Trial of SSGJ-707 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Willing to participate in the study voluntarily, agree to comply with and complete all study procedures, and sign the Informed Consent Form (ICF).\n2. At least 18 years of age at the time of signing the ICF, regardless of gender.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.\n4. Life expectancy of at least 12 weeks.\n5. Histologically or cytologically confirmed locally advanced (Stage IIIB\u002FIIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).\n6. No prior systemic anti-tumor treatment for locally advanced or metastatic NSCLC.\n7. At least one measurable tumor lesion as a target lesion according to RECIST v1.1 criteria.\n\nExclusion Criteria:\n\n1. Presence of small cell carcinoma components in histological pathology.\n2. Presence of EGFR-sensitive mutations or ALK fusion-positive NSCLC.\n3. Known BRAF V600E mutation, MET exon 14 skipping mutation, NTRK fusion, RET fusion, or ROS1 fusion-positive NSCLC.\n4. Presence of brainstem, leptomeningeal, spinal cord metastasis or compression.\n5. Unresolved toxicity from prior anti-tumor treatment, defined as toxicity not returning to NCI CTCAE Version 5.0 Grade 0 or 1.\n6. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n7. History of immunodeficiency; positive for HIV antibodies;\n8. Known active tuberculosis (TB);\n9. Known history of severe allergy to any component of the investigational drug, or history of severe allergic reactions to chimeric or humanized antibodies.\n10. Pregnant or breastfeeding women.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":285,"type":21},420,[287],"PHASE3","This trial is a Phase III study. All patients are stage IIIB\u002FC (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of SSGJ-707 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.",[290],"Advanced Non-Small Cell Lung Cancer","2025-06-23",{"date":293,"type":34},"2025-06-24",{"date":295,"type":34},"2025-06-20",{"date":297,"type":21},"2028-12-31",{"name":40,"class":41},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":4},"100594935","phase-1-a-phase-1-mass-balance-study-of-csss17-in-healthy-chinese-males-100594935","NCT07025915","A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males","A Mass Balance Study of [14C]SSS17 in Healthy Chinese Male Subjects","Inclusion Criteria:\n\n1. Healthy adult male subjects aged 18-45 years .\n2. Body weight ≥50 kg .\n3. Normal findings on comprehensive health assessment.\n4. The subject demonstrates understanding of the trial's objectives, requirements, procedures, and potential adverse reactions; voluntarily participates; commits to complete all trial activities per protocol and comply with study regulations; with the informed consent process conducted in compliance with Good Clinical Practice .\"\n\nExclusion Criteria:\n\n1. Subjects with abnormalities in the nervous system, respiratory system, cardiovascular system, digestive system, hematological and lymphatic systems, endocrine system, or musculoskeletal system that are deemed clinically significant by the investigator.\n2. History of organic heart disease\n3. History of hypersensitivity or allergy to active ingredients.\n4. Average daily smoking \\>5 cigarettes within 3 months prior to screening or inability to abstain during the trial.\n5. Average weekly alcohol intake \\>14 units within 3 months prior to screening or positive alcohol breath test.\n6. History of drug abuse or illicit drug use, or positive urine drug screen.\n7. Participation in any other investigational drug trial within 3 months prior to screening.\n8. Use of any prescription\u002Fnon-prescription medication within 2 weeks prior to investigational product administration.\n9. History of needle\u002Fphobia or inability to tolerate venipuncture.\n10. Hemorrhoids\u002Factive perianal bleeding, chronic constipation\u002Fdiarrhea or positive fecal occult blood test at screening.\n11. Occupational radiation exposure;\n12. Pregnancy plans during or within 1 year post-trial, or refusal to use strict contraception by subject\u002Fpartner during and within 1 year post-trial.",{"count":307,"type":21},6,[55],"This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of \\[¹⁴C\\]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential information for its rational clinical use.",[311],"Healthy Subjects (HS)","2025-06-19",{"date":314,"type":34},"2025-06-25",{"date":316,"type":21},"2025-06",{"date":318,"type":21},"2025-07",{"name":40,"class":41},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":342,"locationsCount":42},"100593553","phase-2-phase-iia-trial-of-oral-sss17-for-post-arthroplasty-anemia-100593553","NCT07007936","Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate the Efficacy and Safety of Oral SSS17 Capsules in the Treatment of Anemia Following Total Hip or Knee Arthroplasty","Inclusion Criteria:\n\n1. Signed informed consent obtained\n\n   \\-\n2. Age 18-70 years (inclusive)\n\n   \\-\n3. Candidates for hip\u002Fknee arthroplasty\n\n   \\-\n4. No DVT on pre-op venous ultrasound\n\n   \\-\n5. Screening Hb 80-110 g\u002FL (no transfusion indication) - 6. Commitment to effective contraception\n\nExclusion Criteria:\n\n1. Hypersensitivity to the investigational product or any of its components\n2. Any other condition causing chronic anemia\n3. Coagulopathy or unstable anticoagulant dosing during screening\n4. Any of the following laboratory abnormalities at screening:\n\n   1. Serum albumin \\\u003C35 g\u002FL\n   2. ALT or AST \\>3×ULN\n5. Active infections or carrier status including:\n\n   * Known HIV infection\n   * Active syphilis\n   * Active HBV infection (HBsAg-positive with HBV DNA \\>10³ copies\u002FmL)\n   * Active HCV infection (anti-HCV positive with detectable HCV RNA)\n6. Acute joint injury with active trauma or infection at screening\n7. Cognitive impairment or psychiatric disorders,current or history of epilepsy\n8. Treatment with ESAs (erythropoiesis-stimulating agents) or HIF inhibitors within 30 days prior to dosing\n9. History of severe thromboembolic events or hematopoietic disorders\n10. Malignancy history\n11. Severe cardiovascular diseases including:\n\n    * Unstable coronary artery disease\n    * Heart failure (NYHA Class III\u002FIV)\n    * Myocardial infarction\u002Fstroke 12 .Poorly controlled hypertension\n\n13\\. Alcohol abuse 14.Pregnancy or lactation 15.Participation in other drug trials within 3 months prior to enrollment 16.Any other condition deemed by the Investigator to compromise subject safety or trial validity","70 Years",{"count":329,"type":21},90,[24],"To assess the safety, tolerability, efficacy, and pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.",[333,334,335],"Postoperative Anemia","Arthroplasty, Replacement, Hip","Arthroplasty, Replacement, Knee","2025-06-06",{"date":338,"type":34},"2025-06-11",{"date":318,"type":21},{"date":341,"type":21},"2026-04",{"name":40,"class":41},{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":42},"100593612","phase-1-phase-i-study-of-sss40-injection-for-moderate-to-severe-bone-metastatic-cancer-pain-100593612","NCT07008703","Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","Phase Ib\u002FIIa Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetic Characteristics of SSS40 in Subjects With Moderate to Severe Bone Metastasis Cancer Pain","Inclusion Criteria:\n\n1. The subjects voluntarily sign an informed consent form, voluntarily participate in the trial, and are willing and able to receive medication, examination, visits, and other related operations according to the trial protocol;\n2. When signing the informed consent form, adult male or female subjects aged ≥ 18 years old；\n3. Previous medical records confirm that the subject has cancer and is diagnosed with bone metastasis; During screening or within 120 days prior to screening visits, Confirming bone metastasis through imaging according to local medical standards, such as bone scans, magnetic resonance imaging (MRI), computed tomography (CT) scans, or positron emission computed tomography (PET-CT) Scanning, diagnosed as bone metastasis based on CT\u002FMRI\u002FPET-CT. If the above examination is not performed within 120 days, a bone scan confirmation is required. If imaging only involves bone scanning, additional CT, MRI, or PET is required to confirm bone metastasis；\n4. Weight ≥ 40kg during screening；\n5. Expected survival time ≥ 3 months；\n6. Pain at the site of cancer bone metastasis, with an average pain score of ≥ 4 points at the designated pain point of bone metastasis (screening period and baseline evaluation period of 3 days)；\n7. When screening, the Eastern Oncology Collaborative Group (ECOG) physical condition score was ≤ 2 points；\n8. The subjects are willing not to use prohibited drugs throughout the entire study period；\n9. The subjects are willing to refrain from using chemotherapy drugs with significant bone marrow suppression from 14 days before administration to 28 days after administration. Among them, drugs with significant bone marrow suppression include paclitaxel (PTX), docetaxel (TXT), vinorelbine (NVB), tiniposide (VM-26), vindesin (VDS), etoposide (VP-16), carboplatin (CBP), mitoxantrone (MITX), nitrogen mustard (HN2), daunorubicin (DNR), and doxorubicin (ADM) \\[THP, MTX, 6-MP, and IFO\\]；\n10. During screening, the bone marrow function of the subjects meets the following requirements (if necessary, can be repeated for confirmation): a. Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3 or ≥ 1.5 × 109\u002FL; b. Platelet count ≥ 90000\u002Fmm3 or ≥ 90 × 109\u002FL; c. Hemoglobin ≥ 70.0 g\u002FL；\n11. When screening, the renal function meets the following requirements (if necessary, repeat the examination to confirm): a Estimated glomerular filtration rate ≥ 30 mL\u002Fmin, and b. Urinary protein\\\u003C2+；\n12. During screening, liver function meets the following requirements (if necessary, can be repeated for confirmation): a. Total serum bilirubin ≤ 1.5 × ULN; b. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5.0 if the tumor affects the liver) × ULN; c. Alkaline phosphatase ≤ 5 × ULN；\n13. If the subject is not currently receiving anticoagulant therapy, the international standardized ratio (INR) or prothrombin time (PT) during screening should be less than 1.5 × ULN (can be double checked to confirm if necessary). Subjects currently receiving anticoagulant therapy must have an INR within the recommended range applicable to their clinical status；\n14. Female participants of childbearing age must agree to use reliable contraceptive measures within 6 months after the start of the study medication and have no plans to conceive or donate eggs; Male participants must agree to use reliable contraceptive measures within 6 months of starting the study medication and have no plans for childbirth or sperm donation；\n15. The subjects are able to communicate well with the researchers and complete the study in accordance with the research regulations.\n\nExclusion Criteria:\n\n1. During screening, there was hypercalcemia (blood calcium concentration ≥ 2.75mmol\u002FL or 11.0mg\u002FdL)；\n2. The pain of the subjects is caused by reasons unrelated to cancer bone metastasis (such as intestinal obstruction\u002Fperforation, spinal cord compression, brain metastasis, pathological fractures or near fractures, etc.)；\n3. The pain of the subjects is neuropathic pain, visceral pain, or unknown in nature, caused by previous anti-tumor treatment, infection, or other reasons mainly unrelated to bone metastasis；\n4. Subjects with brain or meningeal metastases (patients with stable brain metastases can be included in this study)；\n5. Starting systemic treatment for primary malignant tumors or bone metastases within 14 days prior to the first day of the baseline assessment period, including chemotherapy and hormone therapy (excluding those who have received stable treatment for at least 30 days prior to the first day of the baseline assessment period and still meet the inclusion criteria for bone pain severity)；\n6. Individuals who have developed peripheral neuropathy and unstable neuropathy after receiving radiation therapy for bone metastases within 30 days prior to the first day of the baseline evaluation period；\n7. Individuals who receive unstable radiation therapy within 30 days prior to the first day of the baseline evaluation period or experience a significant decrease in NRS score (by more than 3 points) after radiation therapy；\n8. Starting within 30 days prior to the baseline evaluation period, unstable doses of adjuvant analgesic therapy (such as unstable doses combined with single agent acetaminophen (paracetamol), serotonin\u002Fnorepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antiepileptics, bisphosphonates, desukumab, corticosteroids or muscle relaxants, etc.) should be used；\n9. Diagnosed as knee or hip arthritis or Kellgren Lawrence grade ≥ 2 according to the American Rheumatology Association (ACR) and clinical and imaging standards；\n10. Screening for major injuries or surgeries in major joints (such as hip, knee, or shoulder) within the previous year; Individuals with a history of osteonecrosis or osteoporotic fractures (i.e., subjects with osteoporosis and mild traumatic or non traumatic fractures) or a history of joint related events, such as meniscus or knee ligament injuries (with or without surgical repair) or joint infections；\n11. Imaging atlas, determined by researchers, with imaging evidence indicating any of the following diseases during screening: a) rapidly progressive osteoarthritis, b) atrophic or malnourished osteoarthritis, c) subchondral incomplete fractures, d) spontaneous knee joint osteonecrosis (SPONK), e) osteonecrosis, f) pathological fractures, g) neuroarthritis (Charcot's joint), h) crystalline arthritis, i) rheumatoid arthritis, j) lupus erythematosus, k) Significant knee joint effusion or active infection, l) shoulder osteoarthritis and other diseases. Note: i. Patients with bone necrosis secondary to radiotherapy (i.e. radiation-induced osteonecrosis) and related to bone metastasis (i.e. involving the tumor bone interface) are allowed to participate in this study. Ii. Subjects with pathological vertebral fractures with vertebral body damage less than 50% and no spinal canal damage are allowed to participate in this study. Iii. Subjects with pathological fractures of non weight-bearing bone (such as humerus) that have been treated (such as fixation) and have healed, if the fracture does not involve the large joint, can participate in this study；\n12. Individuals with a clinically significant history of heart disease, including those classified by the New York Heart Association as grade III or IV congestive heart failure, left ventricular insufficiency ejection fraction\\\u003C35%, ischemic heart disease, surgical treatment for coronary artery disease, and significantly abnormal electrocardiograms (resting tachycardia (heart rate ≥ 120 beats\u002Fmin) or resting bradycardia (heart rate ≤ 45 beats\u002Fmin) within the first 6 months of screening；\n13. Diagnosed as transient ischemic attack or stroke with sequelae (such as aphasia, significant motor or sensory dysfunction) within the first 6 months of screening；\n14. A clinically significant history, diagnosis, or symptoms and signs of neurological diseases, including but not limited to: a Alzheimer's disease or other types of dementia; b. Head trauma with clinical significance within the past year; c. Peripheral neuropathy or autonomic neuropathy (including chemotherapy related peripheral neuropathy); d. Epilepsy or epilepsy related diseases, with a history of epileptic seizures within 2 years prior to screening; e. Myopathy；\n15. Individuals with an overall impact score greater than 7 on the Autonomous Neurological Symptom Survey (SAS) during screening；\n16. Individuals with a history of carpal tunnel syndrome (CTS) and experiencing symptoms or signs of CTS within the year prior to screening；\n17. Individuals with a history of allergic reactions or rapid allergic reactions to therapeutic or diagnostic monoclonal antibodies or IgG fusion proteins；\n18. Positive cases of active hepatitis, HIV infection, and Treponema pallidum infection were found during screening；\n19. Vaccination received one month before screening；\n20. Screening for individuals with a significant history of alcohol abuse, abuse of analgesics or anesthetics within the first 6 months (excluding medications currently under treatment)；\n21. Previous exposure to exogenous nerve growth factor or anti nerve growth factor antibodies；\n22. Participate in other clinical studies within 30 days prior to the baseline evaluation period (90 days for investigational biologics)；\n23. The presence of severe acute or chronic diseases, mental disorders, or laboratory test abnormalities may increase the risk of subjects participating in this study or receiving treatment with study drugs, or may affect the interpretation of the research results. According to the judgment of the researchers, these conditions may make the subjects unsuitable to participate in this study.",{"count":351,"type":21},132,[55,24],"This is a Phase Ib\u002FIIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer pain. The study includes two stages: a single-arm, open-label, dose-escalation and dose-expansion Phase Ib followed by a randomized, double-blind, placebo-controlled Phase IIa.",[355],"Cancer Pain","2025-05-29",{"date":336,"type":34},{"date":359,"type":34},"2024-03-27",{"date":361,"type":21},"2025-12",{"name":40,"class":41},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":42},"100564453","phase-1-safety-tolerability-and-pharmacokinetic-characteristics-of-sss11-in-patients-with-gout-and-hyperuricemia-100564453","NCT06629376","Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia","Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacological Studies of SSS11 in Patients With Gout and Hyperuricemia After Multiple Administrations, Dose Escalation, Randomized Double-blind, Placebo-controlled Trials","Inclusion Criteria:\n\n* A patient with clinical diagnosis of gout (according to the 2015 ACR\u002FEULAR gout classification criteria), non acute attack phase, and hyperuricemia {under normal purine diet, blood uric acid\\>420 µ mol\u002FL (7 mg\u002Fdl) not tested twice on an empty stomach on the same day}。\n* Screening period blood uric acid\\>420 µ mol\u002FL (7mg\u002Fdl)。\n\nExclusion Criteria:\n\n* Within 14 days prior to enrollment (or within 5 half lives of the drug, whichever is longer), medication that lowers uric acid levels or affects uric acid levels and related drugs (allopurinol, febuxostat, benzbromarone, probenecid, benzenesulfonazolone, Tongyifengning tablets, etc.) must be taken, or during the study period, other drugs that lower uric acid levels or affect uric acid levels and related drugs other than experimental drugs must not be discontinued。\n* Patients with acute gout attacks within 14 days prior to enrollment。\n* Previously received uric acid oxidase or treated with similar drugs such as pegolase or rabulidase。\n* Individuals with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD enzyme activity levels below the lower limit of normal。\n* Individuals with a history of catalase deficiency or evidence that meets the diagnostic criteria for catalase deficiency。\n* Malignant tumor patients (whether treated or not)。",{"count":262,"type":21},[55],"This is a safety, tolerability, pharmacokinetics, and preliminary pharmacological study of multiple administration, dose escalation, randomized double-blind, placebo-controlled.The main purpose of this experiment is to evaluate the safety and tolerability of multiple injections of PEGylated recombinant Candida urate oxidase (test drug code: SSS11) in patients with gout and hyperuricemia.The experimental period includes a screening period of 4 weeks, a treatment period of 4 or 8 weeks, and an observation period of 4 weeks。",[374,375],"Gout","Hyperuricemia","2025-05-26",{"date":378,"type":34},"2025-05-28",{"date":380,"type":34},"2023-11-20",{"date":382,"type":21},"2027-08-08",{"name":40,"class":41},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":42},"100588672","phase-1-a-phase-i-clinical-study-of-sss59-monotherapy-in-patients-with-advanced-malignant-tumors-100588672","NCT06944444","A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors","A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Histologically and\u002For cytologically documented local advanced or recurrent or metastatic malignancies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n* Must have adequate organ function.\n\nExclusion Criteria:\n\n* Any remaining AEs \\> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth.\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Underwent major surgery within 4 weeks prior to first dosing.\n* The patient is participating in another clinical study, unless it is an observational (non-intervention) clinical study or a follow-up period of an intervention study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":392,"type":21},154,[55],"This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.",[396],"Malignant Tumors","2025-04-27",{"date":399,"type":34},"2025-04-29",{"date":397,"type":34},{"date":402,"type":21},"2027-12-31",{"name":40,"class":41},{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":4},"100581743","phase-2-study-of-sss06-for-chemotherapy-induced-anemia-in-non-myeloid-malignancies-100581743","NCT06854276","Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies","A Randomized, Open-Label, Active-Controlled, Multicenter Phase II\u002FIII Clinical Study to Evaluate the Safety and Efficacy of SSS06 in the Treatment of Chemotherapy-Induced Anemia in Patients with Non-Myeloid Malignancies","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of signing the informed consent.\n* Histologically or cytologically confirmed diagnosis of non-myeloid malignancies.\n* Chemotherapy-induced anemia defined as hemoglobin (Hb) ≤100 g\u002FL at screening, with a documented decrease in Hb of ≥10 g\u002FL post chemotherapy initiation, as judged by the investigator.\n* Serum ferritin ≥50 ng\u002FmL and transferrin saturation (TSAT) ≥10% at screening.\n* Body weight ≥40 kg at screening.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or 2 at screening.\n* Expected survival ≥6 months.\n* Planned to receive at least 8 weeks of myelosuppressive chemotherapy starting from Day 1 of the study.\n* Childbearing women must agree to use reliable contraception and have no plans to conceive or donate eggs from the start of study drug administration until 6 months post-last dose. Men must agree to use reliable contraception and have no plans to father a child or donate sperm from the start of study drug administration until 6 months post-last dose.\n* Voluntarily sign informed consent, willing to participate in the trial, and able to comply with the protocol requirements for administration and follow-up, including examinations, visits, and other procedures.\n\nExclusion Criteria:\n\n* Patients undergoing myelosuppressive chemotherapy with an expected curative outcome.\n* Subjects receiving only hormone therapy, biologics, immunosuppressants (e.g., PD-1 and PD-L1 immune checkpoint inhibitors), or targeted therapies, or radiation therapy to treat\u002Fcontrol their tumors; however, subjects receiving chemotherapy in combination with these therapies may be included.\n* Subjects with a hematocrit (HCT) ≥ 36%.\n* Subjects who have undergone interventions (e.g., blood transfusion, erythropoiesis-stimulating agents (ESAs), or hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs)) to elevate hemoglobin (Hb) levels to meet chemotherapy safety standards prior to the initiation of the scheduled chemotherapy regimen.\n* Subjects who received red blood cell (RBC) transfusions, ESAs, or HIF-PHIs within 4 weeks prior to enrollment.\n* Subjects with abnormal liver or kidney function test results: alanine aminotransferase (ALT) \\> 3×ULN, aspartate aminotransferase (AST) \\> 3×ULN, or total bilirubin (TBL) \\> 1.5×ULN (subjects with TBL up to 2×ULN may be included if ALT\u002FAST are within normal limits and the investigator deems no safety concerns). Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (calculated using the CKD-EPI formula).\n* Subjects with active systemic infections requiring treatment.\n* Subjects with a history of clinically significant cardiovascular disease, including New York Heart Association (NYHA) Class III or IV heart failure within the past 6 months, uncontrolled hypertension or hypotension, or severe valvular or endocardial disease history that may increase the risk of thromboembolic events.\n* Subjects who experienced thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack) within the past 6 months.\n* Subjects with clinically significant anemia due to other causes, such as iron deficiency, vitamin B12 or folate deficiency, autoimmune anemia, hemolysis, hemorrhage, or genetic anemias (e.g., sickle cell anemia or thalassemia).\n* Subjects with clinically significant or uncontrolled chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, Crohn's disease, celiac disease).\n* Subjects with severe or active liver disease.\n* Subjects planning to undergo major surgery during the treatment period (surgery with minimal blood loss that does not affect Hb concentration is exempt).\n* Subjects with myeloid malignancies.\n* Subjects with primary or metastatic malignant tumors in the central nervous system.\n* Subjects testing positive for human immunodeficiency virus (HIV) antibodies or syphilis antibodies.\n* Subjects positive for hepatitis B virus (HBV) or hepatitis C virus (HCV):\n\n  1. Subjects with inactive HBsAg carriers or stable hepatitis B patients (HBV DNA \\\u003C 500 IU\u002FmL) may be included, with regular monitoring of HBV DNA during the study as recommended by the investigator.\n  2. Subjects with HCV antibody positivity (HCV-Ab+) may be included if HCV RNA is negative, with regular monitoring of HCV RNA during the study as recommended by the investigator.\n* Subjects who have used any investigational drugs within 4 weeks prior to Day 1 of treatment or plan to use such drugs during the clinical trial.\n* Subjects with a history of alcoholism, drug abuse, or addiction.\n* Subjects deemed unsuitable for participation in the study by the investigator.",{"count":412,"type":21},80,[24],"This study employs a multicenter, randomized, open-label, positive drug-controlled, multiple ascending dose clinical trial design to comprehensively evaluate the safety, tolerability, immunogenicity, and pharmacokinetic characteristics of SSS06 injection in patients with chemotherapy-induced anemia from non-myeloid malignancies, while also exploring its potential efficacy.",[416,417],"Chemotherapy-induced Anemia","Non-myeloid Malignancies","2025-02-25",{"date":420,"type":34},"2025-03-03",{"date":422,"type":21},"2025-03-01",{"date":424,"type":21},"2027-12-01",{"name":40,"class":41},""]